ArticleCPT: pharmacometrics & systems pharmacology2025
Less Is More: Design Considerations for Interactive Pharmacometrics Tools-A Case Study Using the Model Visualization Platform (MVP) App.
Article in CPT: pharmacometrics & systems pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A computational model-powered platform to inform the development of GalNAc-conjugated siRNA therapeutics.Molecular therapy. Nucleic acids · 2026Article
- Less Is More: Design Considerations for Interactive Pharmacometrics Tools-A Case Study Using the Model Visualization Platform (MVP) App.CPT: pharmacometrics & systems pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The shiny R package has enabled pharmacometrics (PMX) scientists to create and share interactive R-based tools, or "shiny apps". Initially, shiny apps are developed ad hoc (i.e. project specific) to provide simulations, and their complexity have evolved to be more general-purpose and "platform-like" in recent years. Despite their complexity and increased amount of features, an unexplored aspect is the design considerations for user interface and user experience (UI/UX) to optimize end-user interactivity and enjoyment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.